Analyst firms · Leerink Partners · ALGS

Leerink Partners ALGS price target and rating history

Aligos Therapeutics Inc. (ALGS) · Health Care

Leerink Partners rates Aligos Therapeutics Inc. (ALGS) Outperform with a $11 price target, as of its latest action on Mar 11, 2022. It has published 4 rating actions on ALGS since September 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a ALGS price target in the last 12 months, the median target is $45.

Current rating
Outperform
Price target
$11
Median target, all firms
$45
Actions on ALGS
4

Leerink Partners price target on ALGS

$29$20$1020222023202420252026
Leerink Partners price target on ALGS, each point a stated target, September 2021 to March 2022.

Every Leerink Partners rating on ALGS

How other firms rate ALGS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Lake StreetBuy$45May 28, 2026
Cantor FitzgeraldOverweight$20May 21, 2026
JefferiesBuy$48Mar 19, 2026

Questions about Leerink Partners and ALGS

What is Leerink Partners's price target for ALGS?
Leerink Partners's latest stated price target for Aligos Therapeutics Inc. (ALGS) is $11, from its action on Mar 11, 2022.
What is Leerink Partners's rating on ALGS?
Leerink Partners rates ALGS Outperform, a bullish rating, as of Mar 11, 2022.
When did Leerink Partners last change its view on ALGS?
On Mar 11, 2022, Leerink Partners raises its price target to $11 from $10, keeps Outperform.
How does Leerink Partners's ALGS target compare with other analysts?
Across 3 firms with a ALGS price target in the last 12 months, the median target is $45.

More ALGS rating histories

All Leerink Partners ratingsALGS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.